Copenhagen Infrastructure Partners reaches final close of EUR ~2 billion for two new funds
COPENHAGEN, Denmark, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Copenhagen Infrastructure Partners has reached final close for its two new funds, CI Advanced Bioenergy Fund I (CI ABF I) and CI Green Credit Fund I (CI GCF I) with total LP commitments of EUR ~2bn. 2023 has been a record year for CIP, as in addition to this final close announcement, CIP also held first close for its flagship fund, CI V, at EUR 5.6bn.
With commitments from investors across the Nordics, Europe, and Asia Pacific, CI GCF I closed at EUR ~1bn with an additional EUR ~200m in co-investments to date. ABF I closed at EUR 750m. The funds’ investor bases are comprised of institutional investors, primarily pension funds, life insurance companies, sovereign wealth funds, family offices, asset managers, and corporate investors.
The two funds make up integral parts of CIP’s distinct greenfield renewable energy infrastructure focused fund strategies. The Advanced Bioenergy Fund I is expected to contribute substantially to producing clean fuels such as renewable natural gas from food waste, agricultural residues and other organic waste streams, displacing carbon-emitting fuels and mitigating negative environmental impacts from these waste streams. The Green Credit Fund provides debt financing with subordinated risk characteristics for renewable energy projects globally, contributing to decarbonizing the power market.
CI GCF I focuses on providing private project finance debt with subordinated risk characteristics supporting renewable energy projects in Europe, North America, and selective jurisdictions in the Asia Pacific region. The project focus is on green- and brownfield projects in renewable energy infrastructure. The fund’s main focus will be on direct investments, but it also has the ability to participate in risk-sharing transactions.
“Reaching this milestone together with a strong group of global LPs allows us to continue identifying new investment opportunities, and work with strong developers on executing the renewable energy build-out. We believe private credit in the renewable energy space is a natural addition to the strong CIP fund portfolio, and it offers our LPs a new and attractive way to deploy capital into the energy transition while leveraging CIP’s strong skills and heritage,” says Jakob Groot, partner and co-head of CIP’s credit platform with partner Nicholas Blach-Petersen.
As of October 13, 2023, CI GCF I has already closed three investments and committed a total of EUR 236m. The fund has a portfolio of renewable energy infrastructure opportunities across a range of European countries as well as North America, and it continues to see a strong demand for this type of debt capital.
The Advanced Bioenergy Fund I focuses on investments in advanced bioenergy infrastructure, in particular in Europe. It enables institutional investors to contribute to the energy transition and participate in the decarbonization of hard-to-abate sectors through the production of advanced biofuels and biogas – while delivering cost-efficient and circular solutions for environmental and organic waste challenges. Investments will be dark green (as defined in the EU regulation Article 9) based on sustainable feedstock such as waste wood, agricultural biowaste, household biowaste and industrial biowaste. The offtake products include green gas and green fuels, such as renewable natural gas (RNG), liquified natural gas (bio-LNG), and second generation bioethanol.
“We are pleased to welcome the new investors in CI ABF I and are delighted that investors generally share our confidence in the market for advanced bioenergy projects. There is a very strong market demand for green gas and green fuels and circular solutions which is provided by CI ABF I’s investment strategy and underpinned by robust regulatory drivers both in the EU and the US. We have a strong pipeline of projects in these markets that we look forward to progressing even further,” says Thomas Dalsgaard, partner in the Advanced Bioenergy Fund.
On one project, CI ABF I has already taken final investment decision to begin construction, and exclusivity has been secured on several industrial-scale advanced bioenergy projects. The projects are located in Denmark, The Netherlands, Belgium, and Spain and are expected to produce Renewable Natural Gas (RNG) and biogenic CO2 from food waste, industrial waste and agricultural waste.
About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focuses on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.
CIP manages ten funds and has to date raised approximately EUR 26bn for investments in energy and associated infrastructure from more than 150 international institutional investors. CIP has approximately 400 employees and 12 offices around the world. For more information, visit www.cip.com
For further information, please contact:
Thomas Kønig, Partner – Investor Relations | +45 7070 5151 | TKON@cip.com
Stephanie R. Brokhattingen, Partner – Investor Relations | +45 7070 5151 | SBR@cip.com
Oliver Routhe Skov, VP – Head of Media Relations | +45 3054 1227 | ORSK@cip.com
This release does not constitute an offer to sell or the solicitation of an offer to purchase any security. Any investment involves substantial risks including complete loss of capital. There can be no assurance that CIP will be able to implement the strategy described herein or, if implemented, that it will lead to successful results. Similarly, there can be no assurance that CIP will be able to maintain the advantages discussed herein over time or outperform third parties or the financial markets generally.
Certain information contained herein constitutes “forward-looking statements,” which can be identified by the use of terms such as “may,” “will,” “expects,” “intends,” “plans,” “believes,” “estimates” or comparable terminology. Forward-looking statements are subject to a number of known and unknown risks and uncertainties, including without limitation changes in economic conditions, political changes, legal and regulatory requirements, interest rate fluctuations, as well as changes in markets, prospects and competition. There can be no assurance that historical trends will continue. Some of the views expressed herein are the opinions of CIP and should not be construed as absolute statements and are subject to change without notice.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t